Is Glenmark Pharma overvalued or undervalued?

As of 14 November 2025, Glenmark Pharma's valuation grade has moved from fair to expensive, indicating a shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 47.78, an EV to EBITDA of 23.11, and a Price to Book Value of 6.03, all of which suggest that the stock is trading at a premium compared to its earnings and assets.
In comparison to its peers, Glenmark Pharma's PE ratio is significantly higher than that of Sun Pharma, which stands at 36.49, and much higher than Cipla's attractive PE of 22.72. The PEG ratio of 0.19 also highlights that Glenmark's growth prospects may not justify its high valuation relative to its earnings growth. Notably, Glenmark has outperformed the Sensex with a year-to-date return of 17.60% compared to the Sensex's 8.22%, but this performance does not mitigate the concerns regarding its current overvaluation.